Login to Your Account



Small, Medium Biotechs 'Pretty Nervous'

High Court Offers Opinion, But Merck-Integra Fight Remanded

By Randall Osborne


Monday, June 20, 2005

The perpetual tussle between lower drug costs for consumers and higher profits for the shareholders of biotechnology and pharmaceutical firms drew more limelight - if such a thing is possible - with last week's ruling by the U.S. Supreme Court that patent holders cannot stop other firms from starting related research.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription